mRNA-LNP Botulinum Toxin Delivery System
Solution Overview
Problem
The administration of botulinum toxin requires careful handling due to its toxic nature, and repeated use is limited by the risk of antibody development, necessitating alternative delivery methods and formulations that ensure safety and efficacy.
Innovation Solution
The use of mRNA encoding botulinum toxin sequences formulated in lipid nanoparticles (LNPs) for delivery, allowing for topical or injection administration and evading innate immune responses through nucleotide modifications, enhancing translation efficiency and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If botulinum toxin is administered through traditional injection methods, then the toxin can effectively paralyze muscles and block nerve signals, but the toxic nature of the toxin requires extreme care in manufacturing and administration
Solution Approach 1:
The patent uses mRNA as an intermediary to deliver the genetic instructions for botulinum toxin production instead of administering the toxin directly. The mRNA encodes the light chain of botulinum neurotoxin and is delivered via lipid nanoparticles, which mediate the transfer of genetic material into target cells. This intermediary approach allows the body to produce the toxin locally and temporarily, reducing the need for large amounts of purified toxin and minimizing systemic toxicity while maintaining local efficacy.
2Duration of action of moving object
If botulinum toxin is used repeatedly for treatment, then the therapeutic effects can be maintained, but the risk of antibody development limits repeated use
Solution Approach 1:
The patent changes the fundamental parameter of toxin delivery from direct protein administration to genetic material delivery. By using mRNA instead of purified botulinum toxin, the body produces the toxin endogenously in small, controlled amounts that degrade naturally after performing their function. This parameter change from exogenous protein to endogenous production reduces the immunogenicity and risk of antibody formation, allowing for repeated treatments while maintaining therapeutic duration.
3Quantity of substance
If mRNA is formulated in lipid nanoparticles for topical application, then the dose requirement can be met despite low absorption, but the formulation complexity increases
Solution Approach 1:
The patent employs lipid nanoparticles as a composite delivery system that combines lipids with mRNA. The lipid nanoparticle formulation includes ionizable lipids, helper lipids, and PEGylated lipids that work together to protect the mRNA, facilitate cellular uptake, and enable both topical and injectable administration. This composite material approach allows for precise dosing in the nanogram range while managing the complexity through standardized nanoparticle formulations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables safer and more efficient delivery of botulinum toxin, potentially reducing antibody formation and extending the duration of action, while allowing for precise targeting and prolonged protein expression, thus overcoming the limitations of traditional toxin injection.
Implementation Method 1
The toxin-receptor complex is taken up into the cell by endocytosis
Implementation Method 2
evading innate immune responses through nucleotide modifications, enhancing translation efficiency and stability
Implementation Method 3
The light (L) chain interacts with different proteins (synaptosome-associated protein (SNAP) 25, vesicle-associated membrane protein, and syntaxin) in the nerve terminals to prevent fusion of acetylcholine vesicles with the cell membrane
Data Source
AI summary
The present invention relates to a composition for expressing botulinum toxin in target tissue by injecting or topically applying an mRNA product capable of expressing the toxin.